News & Partnering
Learn more about Imvax
For more detail on our progress, behind the scenes at Imvax, or opportunities to collaborate with us to advance the future of immunotherapy, dive in below.
Press releases
Imvax Presents New Data on Personalized Whole-Tumor Derived Immunotherapeutic Platform at 2022 International Cancer Immunotherapy Conference
– Immune responses observed in endometrial cancer and glioblastoma models, complementing prior clinical success in glioblastoma and supporting further development of IEC-001 for the treatment of endometrial... Read more
Imvax to Present New Data on Tumor-Derived Immunotherapy Platform at 2022 International Cancer Immunotherapy Conference
PHILADELPHIA (September 21, 2022) — Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced a poster presentation at the 2022 International Cancer Immunotherapy Conference... Read more
Imvax Named as a PHL Inno Inaugural Fire Awards Honoree
PHILADELPHIA, PA (August 12, 2022) — Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced that it has been named an honoree of the... Read more
Imvax to Present at Two Investor Conferences in May
PHILADELPHIA (May 10, 2022) — Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, announced that Chief Executive Officer John P. Furey will be presenting... Read more
Partnering with us
At Imvax, we know that making transformational therapies a reality takes many minds and different technologies working together. We welcome expressions of interest in collaborating to deliver a new generation of immunotherapies. We are a passionate, patient-focused, data-driven platform company.